BioLife Solutions, Inc.

Historical 13F Holders

Symbol
BLFS
CUSIP
09062W204
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 09062W204 since 12/18/2024, newest first.

Filer % of Class Filed
Glazer Capital, LLC 13G
5.5% 9/24/2026
Event 9/17/2026
T. Rowe Price Investment Management, Inc. 13G/A Amendment 3 7.5% 9/8/2026
Event 8/31/2026
Casdin Capital, LLC 13G
9.7% 6/4/2026
Event 6/4/2026
Casdin Capital, LLC 13D/A Amendment 7
9.7% 5/22/2026
Event 5/20/2026
T. Rowe Price Investment Management, Inc. 13G/A Amendment 2 13.5% 5/15/2026
Event 3/31/2026
Invesco Ltd. 13G/A Amendment 2 4.9% 5/6/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 3 0% 3/26/2026
Event 3/13/2026
Invesco Ltd. 13G/A Amendment 1 8.2% 2/12/2026
Event 12/31/2025
T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 10.8% 1/8/2026
Event 12/31/2025
Casdin Capital, LLC 13D/A Amendment 6
12.4% 10/17/2025
Event 10/15/2025
Casdin Capital, LLC 13D/A Amendment 5
14.0% 8/21/2025
Event 8/15/2025
T. Rowe Price Investment Management, Inc. 13G 8.9% 8/14/2025
Event 6/30/2025
Casdin Capital, LLC 13D/A Amendment 4
15.0% 8/13/2025
Event 8/11/2025
Casdin Capital, LLC 13D/A Amendment 3
16.2% 6/12/2025
Event 6/10/2025
Casdin Capital, LLC 13D/A Amendment 2
18.5% 4/9/2025
Event 4/7/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 15 140 k $5.42 M
2026 Q2 222 50.7 M $1.44 B
2026 Q1 189 50.0 M $953 M
2025 Q4 192 49.3 M $1.19 B
2025 Q3 195 48.5 M $1.23 B
2025 Q2 200 50.9 M $1.10 B
2025 Q1 198 48.7 M $1.14 B
2024 Q4 185 46.8 M $1.21 B
2024 Q3 201 45.5 M $1.14 B
2024 Q2 172 47.3 M $1.01 B
2024 Q1 160 45.5 M $844 M
2023 Q4 152 48.5 M $788 M
2023 Q3 158 43.6 M $602 M
2023 Q2 163 40.6 M $898 M
2023 Q1 178 38.9 M $852 M
2022 Q4 174 39.2 M $714 M
2022 Q3 181 38.4 M $874 M
2022 Q2 167 37.2 M $514 M
2022 Q1 171 35.2 M $800 M
2021 Q4 180 35.1 M $1.31 B
2021 Q3 171 31.7 M $1.34 B
2021 Q2 144 28.0 M $1.25 B
2021 Q1 147 25.4 M $915 M
2020 Q4 145 24.3 M $972 M
2020 Q3 116 22.1 M $641 M
2020 Q2 89 14.9 M $245 M
2020 Q1 80 12.2 M $116 M
2019 Q4 88 10.5 M $170 M
2019 Q3 85 12.7 M $211 M
2019 Q2 75 8.98 M $150 M
2019 Q1 69 8.63 M $154 M
2018 Q4 58 7.92 M $95.2 M
2018 Q3 58 7.64 M $134 M
2018 Q2 50 4.68 M $53.4 M
2018 Q1 32 1.71 M $8.77 M
2017 Q4 31 1.71 M $10.3 M
2017 Q3 24 1.28 M $7.32 M
2017 Q2 15 340 k $813 k
2017 Q1 15 268 k $558 k
2016 Q4 19 267 k $431 k
2016 Q3 17 283 k $518 k
2016 Q2 17 382 k $609 k
2016 Q1 16 357 k $653 k
2015 Q4 13 339 k $736 k
2015 Q3 10 334 k $707 k
2015 Q2 10 291 k $566 k
2015 Q1 15 423 k $681 k
2014 Q4 15 624 k $1.02 M
2014 Q3 15 580 k $1.22 M
2014 Q2 14 578 k $1.32 M